Last reviewed · How we verify
MDX2003
At a glance
| Generic name | MDX2003 |
|---|---|
| Sponsor | ModeX Therapeutics, An OPKO Health Company |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MDX2003 CI brief — competitive landscape report
- MDX2003 updates RSS · CI watch RSS
- ModeX Therapeutics, An OPKO Health Company portfolio CI